Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA. Cancer J Clin 2024;74(3): 229–63.Malignant neoplasms in Russia in 2022 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova, I.V. Lisichnikova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2023. (In Russ.).Злокачественные новообразования в России в 2022 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой, И.В. Лисичниковой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2023.Grande E., Díez J.J., Zafon C., Capdevila J. Thyroid cancer: molecular aspects and new therapeutic strategies. J Thyroid Res 2012;2012:847108. DOI: 10.1155/2012/847108Cancer Genome Atlas Research Network (CGARN). Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159(3):676–90. DOI: 10.1016/j.cell.2014.09.050Ricarte-Filho J., Li S., Garcia-Rendueles M. et al. Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. J Clin Invest 2013;123(11):4935–44. DOI: 10.1172/JCI69766Bounacer A., Wicker R., Caillou B. et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 1997;15(11):1263–73. DOI: 10.1038/sj.onc.1200206Pacini F., Castagna M.G., Cipri C., Schlumberger M. Medullary thyroid carcinoma. Clin Oncol 2010;22(6):475–85. DOI: 10.1016/j.clon.2010.05.002Phay J.E., Shah M.H. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 2010;16(24):5936–41. DOI: 10.1158/1078-0432.CCR-09-0786Differentiated thyroid cancer. Clinical recommendations. 2024. (In Russ.). Available at: https://cr.minzdrav.gov.ru/schema/329_2.Дифференцированный рак щитовидной железы. Клинические рекомендации. 2024. Доступно по: https://cr.minzdrav.gov.ru/schema/329_2.Sciuto R., Romano L., Rea S. et al. Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann Oncol 2009;20(10):1728–35. DOI: 10.1093/annonc/mdp050Gruber J.J., Colevas A.D. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist 2015;20(2):11326. DOI: 10.1634/theoncologist.2014-0313Mazzaferri E.L., Kloos R.T. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86(4):1447–63. DOI: 10.1210/jcem.86.4.7407Melmed S., Polonsky K.S., Larsen P.R., Kronenberg H. Howmones and hormone action. Acta Endocrinol (Buchar) 2016;12(1):113.Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol 2006;91(8):2892–9. DOI: 10.1210/jc.2005-2838Wells S.A. Jr, Asa S.L., Dralle H. et al. American Thyroid Association guidelines task force on medullary thyroid carcinoma. Thyroid 2015;25(6):567–610. DOI: 10.1089/thy.2014.0335Medullary thyroid cancer Clinical recommendations. 2024. (In Russ.). Available at: https://cr.minzdrav.gov.ru/schema/329_2.Медуллярный рак щитовидной железы. Клинические рекомендации. 2024. Доступно по: https://cr.minzdrav.gov.ru/recomend/332_2.Bolotina L.V., Vladimirova L.Yu., Dengina N.V. et al. Tumors of the head and neck. Zlokachestvennye opukholi = Malignant Tumors 2024;14(3s2):160–82. (In Russ.). DOI: 10.18027/2224-5057-2024-14-3s2-1.1-09Болотина Л.В., Владимирова Л.Ю., Деньгина Н.В. и др. Опухоли головы и шеи. Злокачественные опухоли 2024;14(3s2):160–82. DOI: 10.18027/2224-5057-2024-14-3s2-1.1-09Filetti S., Durante C., Hartl D.M. et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol 2022;33(7):674–84. DOI: 10.1016/j.annonc.2022.04.009NCCN Clinical Practice Guidelines Thyroid Carcinoma, version 4.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf.Wirth L., Subbiah V., Worden F. et al. Updated safety and efficacy of selpercatinib in patients with RET fusion-positive thyroid cancer: data from LIBRETTO-001. In: 2023 ESMO Congress; October 20–24, 2023, Madrid, Spain. Available at: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2023/updated-safetyand-efficacy-of-selpercatinib-in-patients-pts-with-ret-activatedthyroid-cancer-data-from-libretto-001.Hadoux J., Brose M.S., Hoff A.O. et al. Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med 2023;389(20):1851–61. DOI: 10.1056/NEJMoa2309719Sherman S.I. Evolution of targeted therapies for thyroid carcinoma. Trans Am Clin Climatol Assoc 2019;130:255–65.Agrawal N., Jiao Y., Sausen M. et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 2013;98(2):E364–9. DOI: 10.1210/jc.2012-2703Al-Jundi M., Thakur S., Gubbi S. et al. Novel targeted therapies for metastatic thyroid cancer – a comprehensive review. Cancers (Basel) 2020;12(8):2104. DOI: 10.3390/cancers12082104Resolution of the expert council on the question of strategy of tyrosine kinase inhibitor therapy initiation in differentiated thyroid cancer. Opukholi golovy i shei = Head and Neck Tumors 2023;13(3):106–10. (In Russ.). DOI: 10.17650/2222-1468-2023-13-3-106-110Резолюция экспертного совета по вопросу стратегии инициации терапии дифференцированного рака щитовидной железы тирозинкиназными ингибиторами. Опухоли головы и шеи 2023;13(3):106–10. DOI: 10.17650/2222-1468-2023-13-3-106-110Instructions for the medical use of the medicinal product Retsevmo™ (registration number LP-No. (002482)-(RG-RU) dated 06/10/2024. (In Russ.). Available at: https://www.vidal.ru/drugs/retsevmo.Инструкция по медицинскому применению лекарственного препарата Рецевмо™ (регистрационный номер ЛП-№ (002482)-(РГ-RU) от 10.06.2024. Доступно по: https://www.vidal.ru/drugs/retsevmo.